Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760095 | 1.00 | PPARA (0.46) | PPARAPPARGLMNASMN1; SMN2NPC1 | |
| SCHEMBL3764186 | 0.90 | SMN1; SMN2 (0.40) | PPARAPPARGLMNASMN1; SMN2NPC1 | |
| SCHEMBL3956286 | 0.88 | SMN1; SMN2 (0.40) | PPARAPPARGLMNASMN1; SMN2NPC1 | |
| SCHEMBL3960922 | 0.87 | LMNA (0.38) | PPARAPPARGLMNASMN1; SMN2NPC1 | |
| SCHEMBL3757081 | 0.85 | PPARA (0.52) | PPARAPPARGLMNAL3MBTL1HTT | |
| SCHEMBL3757083 | 0.85 | PPARA (0.52) | PPARAPPARGLMNAL3MBTL1HTT | |
| SCHEMBL3769055 | 0.82 | PPARA (0.45) | PPARAPPARG | |
| SCHEMBL3769059 | 0.82 | PPARA (0.45) | PPARAPPARG | |
| SCHEMBL3757111 | 0.81 | PPARA (0.49) | PPARAPPARG | |
| SCHEMBL3757115 | 0.81 | PPARA (0.49) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | claimed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | claimed |
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | SLC10A1, CYP11B2, UGT1A1 | PPARA 1132/4885PPARG 636/4885LMNA 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.